Literature DB >> 32052017

To add IT chemotherapy, or not to add, that is the question.

Eudocia Q Lee1.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 32052017      PMCID： PMC7158641          DOI： 10.1093/neuonc/noaa040

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  8 in total

1.  The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal.

Authors:  Emilie Le Rhun; Patrick Devos; Thomas Boulanger; Marion Smits; Dieta Brandsma; Roberta Rudà; Julia Furtner; Johann-Martin Hempel; Tjeerd J Postma; Patrick Roth; Tom J Snijders; Frank Winkler; Sebastian Winklhofer; Antonella Castellano; Elke Hattingen; Jaume Capellades; Thierry Gorlia; Martin Van den Bent; Patrick Y Wen; Martin Bendszus; Michael Weller
Journal:  Neuro Oncol       Date:  2019-05-06       Impact factor: 12.300

2.  EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours.

Authors:  E Le Rhun; M Weller; D Brandsma; M Van den Bent; E de Azambuja; R Henriksson; T Boulanger; S Peters; C Watts; W Wick; P Wesseling; R Rudà; M Preusser
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

3.  Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer.

Authors:  Emilie Le Rhun; Jennifer Wallet; Audrey Mailliez; Marie Cecile Le Deley; Isabelle Rodrigues; Thomas Boulanger; Veronique Lorgis; Jerome Barrière; Yves Marie Robin; Michael Weller; Jacques Bonneterre
Journal:  Neuro Oncol       Date:  2020-04-15       Impact factor: 12.300

Review 4.  Leptomeningeal metastases: a RANO proposal for response criteria.

Authors:  Marc Chamberlain; Larry Junck; Dieta Brandsma; Riccardo Soffietti; Roberta Rudà; Jeffrey Raizer; Willem Boogerd; Sophie Taillibert; Morris D Groves; Emilie Le Rhun; Julie Walker; Martin van den Bent; Patrick Y Wen; Kurt A Jaeckle
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

Review 5.  Chemotherapy delivery issues in central nervous system malignancy: a reality check.

Authors:  Leslie L Muldoon; Carole Soussain; Kristoph Jahnke; Conrad Johanson; Tali Siegal; Quentin R Smith; Walter A Hall; Kullervo Hynynen; Peter D Senter; David M Peereboom; Edward A Neuwelt
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544

6.  ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases.

Authors:  Priya Kumthekar; Shou-Ching Tang; Andrew J Brenner; Santosh Kesari; David E Piccioni; Carey Anders; Jose Carrillo; Pavani Chalasani; Peter Kabos; Shannon Puhalla; Katherine Tkaczuk; Agustin A Garcia; Manmeet S Ahluwalia; Jeffrey S Wefel; Nehal Lakhani; Nuhad Ibrahim
Journal:  Clin Cancer Res       Date:  2020-01-22       Impact factor: 12.531

7.  Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis.

Authors:  Claire Bonneau; Gilles Paintaud; Olivier Trédan; Coraline Dubot; Céline Desvignes; Véronique Dieras; Sophie Taillibert; Patricia Tresca; Isabelle Turbiez; Jacques Li; Christophe Passot; Fawzia Mefti; Emmanuelle Mouret-Fourme; Emilie Le Rhun; Maya Gutierrez
Journal:  Eur J Cancer       Date:  2018-04-07       Impact factor: 9.162

8.  Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.

Authors:  James C H Yang; Sang-We Kim; Dong-Wan Kim; Jong-Seok Lee; Byoung Chul Cho; Jin-Seok Ahn; Dae H Lee; Tae Min Kim; Jonathan W Goldman; Ronald B Natale; Andrew P Brown; Barbara Collins; Juliann Chmielecki; Karthick Vishwanathan; Ariadna Mendoza-Naranjo; Myung-Ju Ahn
Journal:  J Clin Oncol       Date:  2019-12-06       Impact factor: 44.544
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.